EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY

被引：0
|
作者：
D'Haens, Geert
Kobayashi, Taku
Morris, Nathan
Lissoos, Trevor
Hoover, Amy
Li, Xingyuan
Arora, Vipin
Milch, Catherine
Sandborn, William J.
Sands, Bruce E.
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
884
引用
收藏
页码：S214 / S214
页数：1
相关论文
共 50 条
  • [21] EXTENDED INDUCTION RESPONSE OVER TIME IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB IN THE LUCENT-1 AND-2 TRIALS
    Rubin, David T.
    Charabaty, Aline
    Jairath, Vipul
    Walter, James
    McGinnis, Kim
    Moses, Richard
    Maier, Sebastian
    Escobar, Rodrigo
    Baygani, Simin
    Zaremba-Pechmann, Liliana
    Kobayashi, Taku
    GASTROENTEROLOGY, 2024, 166 (05) : S821 - S821
  • [22] Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study
    Danese, S.
    Vermeire, S.
    Zhou, W.
    Pangan, A.
    Siffledeen, J.
    Hebuterne, X.
    Nakase, H.
    Higgins, P.
    Chen, M. H.
    Sanchez-Gonzalez, Y.
    Huang, B.
    Xie, W.
    Liu, J.
    Weinreich, M.
    Pannaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S022 - S024
  • [23] Efficacy and Safety of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 U-ACHIEVE Study
    Danese, Silvio
    Vermeire, Severine
    Zhou, Wen
    Pangan, Aileen
    Siffledeen, Jesse
    Hebuterne, Xavier
    Nakase, Hiroshi
    Chen, Minhu
    Higgins, Peter
    Sanchez-Gonzalez, Yuri
    Huang, Bidan
    Xian, Wangang
    Liu, Jianzhong
    Weinreich, Michael
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S312 - S313
  • [24] Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study
    Vermeire, Severine
    Danese, Silvio
    Zhou, Wen
    Pangan, Aileen
    Greenbloom, Susan
    D'Haens, Geert
    Panes, Julian
    Juillerat, Pascal
    Lindsay, James
    Loftus, Edward V.
    Sandborn, William
    Reinisch, Walter
    Sanchez-Gonzalez, Yuri
    Huang, Bidan
    Xian, Wangang
    Liu, Jianzhong
    Weinreich, Michael
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S357 - S357
  • [25] Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study
    Vermeire, S.
    Danese, S.
    Zhou, W.
    Pangan, A.
    Greenbloom, S.
    D'Haens, G.
    Panes, J.
    Juillerat, P.
    Lindsay, J. O.
    Loftus, E. V., Jr.
    Sandborn, W. J.
    Reinisch, W.
    Gonzalez, Y. Sanchez
    Huang, B.
    Xie, W.
    Liu, J.
    Weinreich, M. A.
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S021 - S022
  • [26] Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial
    Sandborn, W. J.
    Ferrante, M.
    Bhandari, B. R.
    Berliba, E.
    Hibi, T.
    D'Haens, G. Geert R.
    Tuttle, J.
    Krueger, K.
    Friedrich, S.
    Durante, M.
    Arora, V.
    Feagan, B.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S54 - S54
  • [27] Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study
    Louis, Edouard
    Panaccione, Remo
    Parkes, Gareth
    Peyrin-Biroulet, Laurent
    Ferrante, Marc
    Takeuchi, Ken
    Siegmund, Britta
    Levine, Phillip
    Kalabic, Jasmina
    Neimark, Ezequiel
    Wallace, Kori
    Chen, Su
    Duan, W. Rachel
    Armuzzi, Alessandro
    Biedermann, Luc
    Loftus, Edward V.
    Melmed, Gil
    Schreiber, Stefan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S624 - S625
  • [28] Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study
    Louis, Edouard
    Panaccione, Remo
    Parkes, Gareth
    Pevrin-Biroulet, Laurent
    Ferrante, Marc
    Takeuchi, Ken
    Siegmund, Britta
    Levine, Phillip
    Kalabic, Jasmina
    Neimark, Ezequiel
    Wallace, Kori
    Chen, Su
    Duan, W. Rachel
    Armuzzi, Alessandro
    Biedermann, Luc
    Loftus, Edward
    Melmed, Gil
    Schreiber, Stefan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S3 - S3
  • [29] Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials
    D'Haens, Geert
    Higgins, Peter D. R.
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Lee, Scott
    Moses, Richard E.
    Redondo, Isabel
    Escobar, Rodrigo
    Gibble, Theresa Hunter
    Keohane, Anthony
    Morris, Nathan
    Zhang, Xin
    Arora, Vipin
    Kobayashi, Taku
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (12) : 2335 - 2346
  • [30] Efficacy and safety of mirikizumab as maintenance therapy in patients with moderate-severe active ulcerative colitis: phase 3 LUCENT-2 study results
    Dubinsky, Marla C.
    Irving, Peter M.
    Li, Xingyuan
    Howaldt, Stefanie
    Pokrotnieks, Juris
    Krueger, Kathryn
    Laskowski, Janelle
    Lissoos, Trevor
    Milata, Joe
    Morris, Nathan
    Arora, Vipin
    Milch, Catherine
    Sands, Bruce E.
    Dhesi, Endip
    GUT, 2023, 72 (SUPPL_2) : A86 - A87
12345